Hydroxyurea Treatment for Adult Sickle Cell Anemia Patients in Kinshasa
Status:
Completed
Trial end date:
2020-05-16
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy of hydroxyurea (HU) in improving
disease severity in adult patients with sickle cell anemia in Kinshasa (Democratic Republic
of Congo). This study aims to:
- assess the safety and efficacy of HU treatment in the Congolese environment;
- assess the reversibility of chronic cardiac lesions. Participants will take hydroxyurea
for two years. The effects of the treatment will be evaluated periodically by clinical
evaluation, biological tests, and echocardiographic exploration.